Is montelukast effective in regression of endometrial implants in an experimentally induced endometriosis model in rats?. (January 2015)

• Record Type: Journal Article
• Authors: Kiykac Altinbas, Sadiman; Tapisiz, Omer Lutfi; Cavkaytar, Sabri; Simsek, Gulcin; Oguztuzun, Serpil; Goktolga, Umit
• Is Part Of: European journal of obstetrics, gynecology, and reproductive biology. Volume 184(2015:Jan.)
• Page Start: 7
• Page End: 12
• Publication Date: 2015-01
• Subjects: Endometriosis -- Rat -- Montelukast -- MMP-2 -- VEGF; Obstetrics -- Periodicals; Gynecology -- Periodicals; Reproductive health -- Periodicals; Gynecology -- Periodicals; Obstetrics -- Periodicals; Reproduction -- Periodicals; Obstétrique -- Périodiques; Gynécologie -- Périodiques; Reproduction -- Périodiques; Verloskunde; Gynaecologie; Voortplanting (biologie); Gynecology; Obstetrics; Reproduction; Electronic journals; Periodicals; Electronic journals; 618.05
• DOI: 10.1016/j.ejogrb.2014.10.026
• Languages: English
• ISSNs: 0301-2115

Abstract

Abstract: Objective: Montelukast, a selective antagonist of Type 1 cysteinyl leukotriene receptors (CysLT1 Rs), antagonizes the proinflammatory and proasthmatic activities of CysLT1 Rs. We investigated the effect of montelukast on a surgically induced endometriosis rat model. Study design: Thirty-two sexually mature, cycling, female Wistar-Albino rats, in which endometriotic implants were surgically induced, were randomly divided into three groups. Group I [Montelukast (M), 10 rats)] was given 1.6 mg/kg/day of oral montelukast sodium. Group II [Leuprolide acetate (L), 11 rats] was given 1 mg/kg single dose of s.c.leuprolide acetate. Group III [Control (C), 11 rats] received saline solution through an orogastric tube and served as controls. After a 3-weeks medication, the rats were sacrificed to investigate the endometriotic implants for size and morphological and histological characteristics, including immunoreactivity of MMP-2 and VEGF. Results: The mean area of implants decreased from 48.2 ± 24.7 to 29.3 ± 15.8 mm 2 in Group I (M) ( P = 0.008) and from 62 ± 32.1 to 39.9 ± 18.1 mm 2 in Group II (L) ( P = 0.003). In Group III (C), the mean area increased from 41.1 ± 31.1 to 60.4 ± 37.1 mm 2 ( P = 0.025). Histopathological analysis showed statistically significant lower scores in rats treated with montelukast compared to leuprolide and controls. MMP H scores were not different between the groups in both epithelial and stromal MMP-2 immunostaining. VEGF H scores were statistically lower in Group 1 (M) in epithelial VEGF immunostaining when compared to Group II (L) and Group III (C) ( P = 0.006). Conclusion(s): Montelukast may effectively cause a significant decrease in the area of endometriotic implants.